DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Fotivda is a drug marketed by Aveo Pharms and is included in one NDA. There are two patents protecting this drug.
The generic ingredient in FOTIVDA is tivozanib hydrochloride. One supplier is listed for this compound. Additional details are available on the tivozanib hydrochloride profile page.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be April 26, 2022. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
DrugPatentWatch® Estimated Generic Entry Opportunity Date for FOTIVDA
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for FOTIVDA
Identify potential brand extensions & 505(b)(2) entrants
|AVEO Pharmaceuticals, Inc.||Phase 1/Phase 2|
|AstraZeneca||Phase 1/Phase 2|
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|Aveo Pharms||FOTIVDA||tivozanib hydrochloride||CAPSULE;ORAL||212904-001||Mar 10, 2021||RX||Yes||No||Get Started for $10||Get Started for $10||Y||Y||Get Started for $10|
|Aveo Pharms||FOTIVDA||tivozanib hydrochloride||CAPSULE;ORAL||212904-002||Mar 10, 2021||RX||Yes||Yes||Get Started for $10||Get Started for $10||Y||Get Started for $10|
|Aveo Pharms||FOTIVDA||tivozanib hydrochloride||CAPSULE;ORAL||212904-001||Mar 10, 2021||RX||Yes||No||Get Started for $10||Get Started for $10||Y||Get Started for $10|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Exclusivity Expiration|